{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:22:44Z","timestamp":1778325764404,"version":"3.51.4"},"reference-count":52,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Age-related macular degeneration (AMD) is a progressive, chronic disease of the central area of the retina, which, if untreated, leads to blindness. This study aimed to compare the effectiveness of therapy using anti-VEGF drugs, namely brolucizumab and aflibercept, in patients with neovascular AMD (nAMD) during a monitoring period lasting around 20 weeks. The analysis consisted of 40 patients diagnosed with neovascular age-related macular degeneration, with 20 patients receiving aflibercept (Eylea, Bayer) at a dose of 2 mg\/50 \u00b5L into the vitreous chamber at the following intervals\u20143 doses, 4 weeks apart, followed by a fourth dose after 8 weeks. The remaining 20 patients received brolucizumab (Beovu, Novartis) at a dose of 6 mg\/50 \u00b5L, administered in the following schedule\u20143 initial doses, 4 weeks apart, with the administration of a fourth dose decided for each patient individually by the doctor, depending on disease activity, assessed through imaging tests. To evaluate treatment effectiveness, the following measurements were used: \u2018read distance and near visual acuity\u2019 for each eye separately using the Snellen chart; and non-invasive retinal imaging techniques\u2014optical coherence tomography (OCT) and OCT angiography (OCTA). In patients treated using brolucizumab, during the observation period, statistically significant differences were found in the following parameters: flow area (p = 0.0277); select area (p = 0.0277); FOVEA (p = 0.0073); visus (p = 0.0064). In brolucizumab-treated patients, changes in OCT and OCTA, indicating an improvement, were already visible after the first injection of the drug, whereas in the aflibercept-treated group, changes were only visible after the fourth injection. We found a higher effectiveness of brolucizumab therapy compared to aflibercept in patients with nAMD during an observations period lasting 20 weeks. Our observations are significant, although they require further research.<\/jats:p>","DOI":"10.3390\/ijerph19042303","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:25:45Z","timestamp":1645129545000},"page":"2303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration"],"prefix":"10.3390","volume":"19","author":[{"given":"Magdalena","family":"Musia\u0142-Kopiejka","sequence":"first","affiliation":[{"name":"Trauma Centre, Department of Ophthalmology, St. Barbara Hospital, 41-200 Sosnowiec, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Polanowska","sequence":"additional","affiliation":[{"name":"Trauma Centre, Department of Ophthalmology, St. Barbara Hospital, 41-200 Sosnowiec, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-1691","authenticated-orcid":false,"given":"Dariusz","family":"Dobrowolski","sequence":"additional","affiliation":[{"name":"Trauma Centre, Department of Ophthalmology, St. Barbara Hospital, 41-200 Sosnowiec, Poland"},{"name":"Chair and Clinical Department of Ophthalmology, Division of Medical Science in Zabrze, Medical University of Silesia in Katowice, 40-760 Katowice, Poland"},{"name":"Department of Ophthalmology, District Railway Hospital, 40-760 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9737-5391","authenticated-orcid":false,"given":"Katarzyna","family":"Krysik","sequence":"additional","affiliation":[{"name":"Trauma Centre, Department of Ophthalmology, St. Barbara Hospital, 41-200 Sosnowiec, Poland"},{"name":"Department of Ophthalmology, Faculty of Medicine in Zabrze, University of Technology, Academy of Silesia in Katowice, 41-800 Zabrze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-5790","authenticated-orcid":false,"given":"Edward","family":"Wyl\u0119ga\u0142a","sequence":"additional","affiliation":[{"name":"Chair and Clinical Department of Ophthalmology, Division of Medical Science in Zabrze, Medical University of Silesia in Katowice, 40-760 Katowice, Poland"},{"name":"Department of Ophthalmology, District Railway Hospital, 40-760 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-7145","authenticated-orcid":false,"given":"Beniamin Oskar","family":"Grabarek","sequence":"additional","affiliation":[{"name":"Department of Histology, Cytophysiology and Embryology, Faculty of Medicine, University of Technology, Academy of Silesia in Katowice, 41-800 Zabrze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-8020","authenticated-orcid":false,"given":"Anita","family":"Lyssek-Boro\u0144","sequence":"additional","affiliation":[{"name":"Trauma Centre, Department of Ophthalmology, St. Barbara Hospital, 41-200 Sosnowiec, Poland"},{"name":"Department of Ophthalmology, Faculty of Medicine in Zabrze, University of Technology, Academy of Silesia in Katowice, 41-800 Zabrze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMcp2102061","article-title":"Age-related macular degeneration","volume":"385","author":"Apte","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thoongsuwan, S., Hanutsaha, P., Chantarasorn, Y., Ruamviboonsuk, P., Vongkulsiri, S., and Kungwanpongpun, P. (2022). Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand: A Retrospective Real-World Study (TOWER Study). Ophthalmol. Ther., 1\u201319.","DOI":"10.1007\/s40123-022-00471-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in agerelated macular degeneration: A review","volume":"12","author":"Yassin","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Marchesi, N., Fahmideh, F., Boschi, F., Pascale, A., and Barbieri, A. (2021). Ocular Neurodegenerative Diseases: Interconnection between Retina and Cortical Areas. Cells, 10.","DOI":"10.3390\/cells10092394"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: A report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_9","first-page":"S3","article-title":"Optimizing anti- VEGF treatment outcomes for patients with neovascular agerelated macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_10","first-page":"557","article-title":"Autophagy: A new mechanism for regulating VEGF and PEDF expression in retinal pigment epithelium cells","volume":"12","author":"Li","year":"2019","journal-title":"Int. J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1042\/CS20170066","article-title":"Negative regulators of angiogenesis: Important targets for treatment of exudative AMD","volume":"131","author":"Farnoodian","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dammak, A., Huete-Toral, F., Carpena-Torres, C., Martin-Gil, A., Pastrana, C., and Carracedo, G. (2021). From Oxidative Stress to Inflammation in the Posterior Ocular Diseases: Diagnosis and Treatment. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091376"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.sjopt.2018.05.002","article-title":"Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy","volume":"32","year":"2018","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","article-title":"Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex","volume":"33","author":"Bhutto","year":"2012","journal-title":"Mol. Asp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kaarniranta, K., Pawlowska, E., Szczepanska, J., Jablkowska, A., and Blasiak, J. (2019). Role of mitochondrial DNA damage in ROS-mediated pathogenesis of age-related macular degeneration (AMD). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102374"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-319-75402-4_2","article-title":"Mitochondria: Potential targets for protection in age-related macular degeneration","volume":"1074","author":"Brown","year":"2018","journal-title":"Retin. Degener. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/bjophthalmol-2020-316195","article-title":"Gene therapy for neovascular age-related macular degeneration: Rationale, clinical trials and future directions","volume":"105","author":"Georgiou","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_21","first-page":"S172","article-title":"Review of neovascular age-related macular degeneration treatment options","volume":"25","author":"Holekamp","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14740338.2019.1643838","article-title":"Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: An update","volume":"18","author":"Costagliola","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_23","unstructured":"(2021, December 23). Summary of Product Characteristics: Aflibercept. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf."},{"key":"ref_24","unstructured":"(2021, December 23). Summary of Product Characteristics: Brolucizumab. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200213147089\/anx_147089_en.pdf."},{"key":"ref_25","first-page":"5194","article-title":"Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER","volume":"60","author":"Singh","year":"2019","journal-title":"Investig. Ophthalm. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: Results of the randomized phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1364\/BOE.379150","article-title":"Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema","volume":"11","author":"Rasti","year":"2020","journal-title":"Biomed. Opt. Express"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/08820538.2019.1641526","article-title":"Intravitreal Ziv-Aflibercept: A comprehensive review","volume":"Volume 34","author":"Kapoor","year":"2019","journal-title":"Seminars in Ophthalmology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","article-title":"Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy","volume":"9","author":"Jung","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","article-title":"Brolucizumab and immunogenicity","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2020.07.028","article-title":"On-Label and Off-Label Clinical Studies of FDA\u2013Approved Ophthalmic Therapeutics","volume":"128","author":"Gopal","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00417-020-05059-y","article-title":"Switching anti-VEGF agent for wet AMD: Evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting","volume":"259","author":"Granstam","year":"2021","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: First approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_35","first-page":"1455","article-title":"Predictability of the 12-week dosing status at week 48 for patients receiving brolucizumab in HAWK and HARRIER","volume":"59","author":"Dugel","year":"2018","journal-title":"Investig. Ophthalm. Vis. Sci Conf."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bulirsch, L.M., Sa\u00dfmannshausen, M., Nadal, J., Liegl, R., Thiele, S., and Holz, F.G. (2021). Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br. J. Ophthalmol.","DOI":"10.1136\/bjophthalmol-2020-318672"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Challenges and opportunities in cancer drug resistance","volume":"121","author":"Ward","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1208\/s12248-016-0018-8","article-title":"Validation of a drug-resistant anti-adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of adalimumab","volume":"19","author":"Bian","year":"2017","journal-title":"AAPS J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3389\/fimmu.2020.01431","article-title":"New Insights into Immunological Therapy for Retinal Disorders","volume":"11","author":"Takeda","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/a-1101-9126","article-title":"A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE)","volume":"237","author":"Garweg","year":"2020","journal-title":"Klin. Mon. Augenheilkd."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: A randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajo.2014.05.025","article-title":"Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration","volume":"158","author":"Fauser","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","article-title":"Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: A comparative review","volume":"4","author":"Khanna","year":"2019","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.10.4.9","article-title":"Durability of VEGF suppression with intravitreal aflibercept and brolucizumab: Using pharmacokinetic modeling to understand clinical outcomes","volume":"10","author":"Eissing","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Chong","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1477-7525-4-97","article-title":"Quality of life in age-related macular degeneration: A review of the literature","volume":"4","author":"Mitchell","year":"2006","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archopht.116.4.514","article-title":"The psychosocial impact of macular degeneration","volume":"116","author":"Williams","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fimmu.2017.00653","article-title":"Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases","volume":"8","author":"Fernandes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: A randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MAbs"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/4\/2303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:21:37Z","timestamp":1760134897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/4\/2303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijerph19042303"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19042303","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}